News Industry News Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology August 15, 2017
News Industry News Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent July 25, 2017
News Industry News AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot May 26, 2017
News Industry News Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT October 30, 2016
News Industry News FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa October 20, 2015
News Industry News Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT October 14, 2015
News Industry News Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI September 09, 2015
News Industry News New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events September 08, 2015
News Industry News US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack September 03, 2015
News Industry News First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate) July 29, 2015
News Industry News NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults July 13, 2015
News Industry News The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin) July 09, 2015
News Industry News Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C June 25, 2015